Thus, the carrier protein was the major differential factor of the conjugate vaccines. In the Diosmetin present study, PS14-Hc and PS23F-Hc were demonstrated to potentiate a robust PS-specific antibody response at the levels comparable to the TT- and CRM197-based controls. levels comparable to the controls. Thus, Hc exhibited a practical carrier effect to help the pneumococcal conjugate vaccines perform good immunogenicities. == 1. Introduction == The encapsulated bacteria with capsular polysaccharide (PS), asStreptococcus pneumonia,Haemophilus influenzaetype b, andNeisseria meningitidis, cause severe morbidity and mortality worldwide [1]. Due to the increasing bacterial resistance to antibiotics, effective vaccinations are urgently required to protect from the encapsulated bacteria-caused diseases [2,3]. Capsular PS is an important virulence determinant of the encapsulated bacteria and has been used as an antigen for preventive vaccine development [4,5]. However, the PS vaccines elicit poor T cell-independent immune responses without long-term immunological remembrances, particularly in children and the aged [6,7]. The conjugate vaccines have been produced by covalent conjugation of the antigenic PS with a nontoxic carrier protein to enhance the immunogenicity of PS vaccines [810]. After priming with the carrier protein, the immune response of PS improved by increasing the number of T lymphocytes [11,12]. The carrier protein can also anchor PS Diosmetin to the B cell MHC-II, which makes the carbohydrate moiety present to T cell and eliciting T cell-dependent response to PS [13,14]. Thus, the conjugate vaccines have been demonstrated to be immunogenic and capable of inducing immunological memory and high avidity [15]. Tetanus toxoid (TT) is one of the most commonly used carrier proteins, and TT-based conjugate vaccines have been developed to confer protection against meningococcal and pneumococcal diseases [16]. However, TT is derived fromClostridium tetaniand inactivated with formaldehyde, which suffers from residual harmful formaldehyde [17].C. tetanican resist the inactivation of formaldehyde by forming spores, so it cannot assurance that TT is completely nontoxic [17]. Besides, TT-based conjugate vaccine showed high rates Diosmetin of irritability, crying, and fever. Cross-reactive material 197 (CRM197) is usually a carrier protein used in approved conjugate vaccines, such as Prevnar (Pfizer) againstS. pneumonia[13]. It does not require detoxification with formaldehyde, thus preserves T-helper epitopes and provides more lysyl side chains for conjugation [18]. However, CRM197is classically purified from your culture supernatant ofC. diphtheriaeC7 (197) strain, which suffers from low yield and requires sophisticated culture conditions [19]. Thus, a candidate carrier protein without the disadvantages of the two proteins is usually urgently needed for the conjugate vaccines. The native C-fragment of tetanus toxin (Hc) is usually a well-defined protein that retains many properties such as low allergenicity, low toxicity, binding activities to gangliosides, and immunogenic potency [20]. Due to its advantages in production, characterization, and homogeneity, Hc is a good substitute for TT in Diosmetin the production of tetanus antitoxin [21,22]. Moreover, Hc could be purified with high yield by a three-step purification based on affinity chromatography. Pneumococcal serogroups 14 and 23F have been proved to be a leading cause of pneumococcal infections, and their capsular PSs (PS14 and PS23F) are essential virulence determinants [23,24]. In the present study, PS14 and PS23F were conjugated with Hc, TT, and CRM197, respectively. The carrier effect of Hc to enhance the immunogenicity of the conjugate pneumococcal vaccines was thus evaluated. TT-based and CRM197-based conjugates acted as controls for Hc-based ones (PS14-Hc and PS23F-Hc). PS14-Hc and PS23F-Hc were both proved to potentiate a strong PS-specific humoral immunity. The biophysical and immunological properties of PS14-Hc and PS23F-Hc were investigated. The study could rationalize the carrier effect of Hc to enhance the immunogenicity of the conjugate pneumococcal vaccines. == 2. Materials and Methods == Diosmetin == 2.1. Materials and Animals == 2-iminothiolane (IT), bovine serum albumin (BSA), 5,5-dithio-bis-(2-nitrobenzoic acid), andN-(2-aminoethyl) maleimide (AM) were purchased from Rabbit polyclonal to LRP12 Sigma (USA). Horseradish peroxidase- (HRP-) conjugated goat anti-mouse antibodies (including HRP-IgM, HRP-IgG, HRP-IgG1, and HRP-IgG2a) were products of Abcam (USA). Pneumococcal PS serogroups 14 and 23F, CRM197, and TT were products of Hualan Biological Engineering Inc. (China). Hc was prepared as explained previously [20]. BALB/c (15-20 g, female) were purchased from Beijing Vital River Laboratory Animal Technologies Co. Ltd. The mice were provided with enough food and water and raised under a comfortable environment. The mouse experiments were approved by the Institutional Animal Care and Use Committee of Beijing Laboratory Animal Research Center (identification code: ZSBD-2017-A034-3R). All operations performed on mice were according to approved methods. The mice were euthanized at the end of the experiment, and all efforts were made to reduce.